# VIR-7831 for the Early Treatment of COVID-19 in Outpatients

> **NCT04545060** · PHASE2,PHASE3 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 1057 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** VIR-7831 (sotrovimab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04545060
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-09-02
- **Target enrollment:** 1057 (ACTUAL)
- **Last updated:** 2022-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04545060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04545060, "VIR-7831 for the Early Treatment of COVID-19 in Outpatients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04545060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*